SCHEMBL29630202

SCHEMBL29630202

O=C(O)c1cccnc1OC(F)F.O=C(O)c1ccco1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 2/20 0.41
TRPV4 Q9HBA0 1/20 0.41
KDM4E B2RXH2 3/20 0.40
POLB P06746 1/20 0.40
NPSR1 Q6W5P4 4/20 0.40
HTT P42858 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 5/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
ALOX12 P18054 1/20 0.39
CCR6 P51684 1/20 0.39
TSHR P16473 2/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
BLM P54132 1/20 0.39
AGER Q15109 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3932209 0.86 NAPRT (0.53) NAPRTTRPV4KDM4ENPSR1HTT
Quinolinic Acid SCHEMBL27759644 0.75 KDM4E (0.67) NAPRTKDM4EPOLBNPSR1HTT
SCHEMBL27931903 0.75 NAPRT (0.50) NAPRTTRPV4KDM4ENPSR1HTT
SCHEMBL9599890 0.73 TRPV4 (0.54) NAPRTTRPV4KDM4ENPSR1TDP1
SCHEMBL20524513 0.73 RAB9A (0.54) NAPRTTRPV4KDM4EHTTALDH1A1
SCHEMBL15694859 0.71 KDM4E (0.52) NAPRTKDM4ENPSR1HTTTDP1
SCHEMBL22259349 0.71 TDP1 (0.60) TRPV4KDM4EPOLBHTTTDP1
Pyridine SCHEMBL28203994 0.70 CES2 (0.54) POLBNPSR1HTTTDP1ALDH1A1
SCHEMBL15662417 0.70 KDM4E (0.50) NAPRTKDM4ENPSR1HTTTDP1
SCHEMBL24446 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2026-03-12 US disclosed
US-12404266-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-09-02 US disclosed
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-28 US disclosed
US-20240336602-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2024-10-10 US disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 NAPRT 1197/4885TRPV4 12/4885KDM4E 4112/4885
US-12404266-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 NAPRT 1197/4885TRPV4 12/4885KDM4E 4112/4885
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM6, TRPV3, TRPM2 NAPRT 1526/4885TRPV4 17/4885KDM4E 4403/4885
US-20240336602-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM6, TRPM2 NAPRT 1197/4885TRPV4 12/4885KDM4E 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.